Harrison.ai
Makes AI that reads X-rays, CT scans and pathology slides for hospitals worldwide.
On the record
Checkpoint: Series D round terms (size, lead investor) and headcount trend disclosure
The call
Harrison.ai has the hospital footprint and regulatory clearances to matter, but a richer rival and unproven revenue leave its next round as the real test.
Harrison.ai makes artificial intelligence software that helps doctors read medical scans like X-rays and CT scans faster and more accurately. It has won official government approvals (FDA clearances) and works in over 1,000 hospitals across 40 countries, which are real accomplishments that take years to achieve. However, a rival company called Aidoc has raised more money, works in almost twice as many hospitals, and has built its own AI foundation model with similar approvals, making it harder for Harrison to stand out. The biggest question is whether Harrison can actually make money from all these hospitals using its software, since the company quietly shrunk its staff by 8 percent last year even though it raised $112 million, which suggests customers may not be paying enough or renewing their contracts.
Why
01
AI pressure: Aidoc (CARE1 foundation model). Aidoc now runs its own FDA-track foundation model across twice as many hospitals as Harrison, in the same radiology AI market. Could AI do the core job? Unlikely.
02
Bigger players: GE HealthCare and Siemens Healthineers. Both hardware giants already sell 80+ FDA-cleared radiology AI tools each and could bundle them free with scanners Harrison depends on. Could a giant copy it? Probably.
03
What protects it. FDA clearances, Medicare NTAP coding, and live workflow integration across 1,000+ hospital sites are hard for a new model to replace fast.
What would change this call
Harrison.ai closes a Series D and discloses its size, valuation and lead investor. Shows whether investors still back its growth after headcount contraction.
Harrison.ai announces signed multi-year US hospital contracts rather than pilots. Shows it can win paying customers against Aidoc in the US market.
Franklin.ai receives FDA clearance with peer-reviewed real-world validation. Shows its pathology product can match Paige's already-validated prostate product.
Harrison.ai announces signed multi-year US hospital contracts rather than pilots. Shows it can win paying customers against Aidoc in the US market.
Franklin.ai receives FDA clearance with peer-reviewed real-world validation. Shows its pathology product can match Paige's already-validated prostate product.
Key numbers
- $112M Series C closed, $240M+ total funding
- Aidoc raised $150M Series E, ~2,000 hospitals
- Headcount fell 8% YoY after Series C raise
Named risks
- Revenue undisclosed and unverified against $240M+ raised, suggesting unproven monetization at scale.
- Headcount contracted 8% YoY (Jul 2026) despite fresh Series C capital and product launches.
- Aidoc's larger, Nvidia-backed war chest and hospital footprint could out-compete Harrison.ai in the US.
- OAIC privacy inquiry into I-MED data-sharing closed without breach finding (Aug 2025) but can be reopened.
- Franklin.ai pathology product remains research-use-only while rival Paige has peer-reviewed NHS validation.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Aidoc | losing to | Aidoc raised $150M Series E (Apr 2026), $500M+ total, ~2,000 hospitals vs Harrison's ~1,000 sites |
| Paige | losing to | Paige Prostate AI got peer-reviewed NHS validation (Jul 2026) while Franklin.ai remains research-use-only (mid-2026) |
| GE HealthCare / Siemens Healthineers | contesting | Hardware giants could bundle their own FDA-cleared radiology AI with imaging equipment sales |
| Viz.ai | contesting | Established incumbent in acute neurovascular AI triage, an adjacent radiology AI segment |
Questions people ask
- Is Harrison.ai profitable in 2026?
- Harrison.ai does not publicly disclose revenue or profit figures. As of February 2025 it had raised over $240M in funding while reporting 1,000+ hospital deployments across 40+ countries (company-reported, October 2025), but no profitability data has been made public.
- Who owns Harrison.ai?
- Harrison.ai is privately held and VC-backed, founded in 2018 by brothers Dr. Aengus Tran and Dimitry Tran. Investors include Blackbird Ventures, Horizons Ventures, Sonic Healthcare, Aware Super, and Australia's National Reconstruction Fund Corporation, which took a $32M stake in January 2025.
- How much money has Harrison.ai raised?
- Harrison.ai closed a $112M Series C in February 2025 co-led by Aware Super, ECP and Horizons Ventures, bringing total funding to over $240M, following an earlier Series B of roughly $91.7-92.3M in December 2021.
- Is Aidoc a bigger threat than Harrison.ai's other competitors?
- Yes, Aidoc is Harrison.ai's closest direct rival: it raised a $150M Series E in April 2026 backed by Goldman Sachs and Nvidia's NVentures, reaching $500M+ total funding and roughly 2,000 hospitals, versus Harrison.ai's ~1,000 sites and $240M+ raised.
- Is Harrison.ai laying off employees?
- Headcount tracker Crustdata reported an 8% year-over-year contraction in Harrison.ai's headcount as of July 2026 (around 220 staff), despite the company closing a $112M Series C in February 2025 and continuing to launch new products.
- Could AI replace Harrison.ai's radiology reports?
- Harrison.ai's own generative model, Harrison.rad.1, was independently tested at Mass General Brigham/ACR's Healthcare AI Challenge in August 2025, producing draft reports rated 65.4% acceptable versus 79.6% for radiologist-written reports, showing AI drafting still trails human radiologists.
Timeline
- 2026-07-14Paige Prostate AI gets peer-reviewed NHS validation across 3 Trusts, a direct challenge to Franklin.ai
- 2026-07-06Harrison.Rad 1.5 technical report published, adding automated report drafting
- 2026-05-24CB Insights lists an I-MED-linked shareholder secondary liquidity transaction
- 2026-04Aidoc raises $150M Series E led by Goldman Sachs with Nvidia's NVentures
- 2025-11Harrison.ai launches zero-markup Open Platform marketplace at RSNA
- 2025-10-07Harrison.ai rebrands Annalise.ai into unified 'Harrison.ai Radiology'
- 2025-08-18MGB/ACR independent challenge rates Harrison.rad.1 reports 65.4% vs 79.6% for radiologists
- 2025-02-11Harrison.ai closes $112M Series C, total funding exceeds $240M
- 2024-09Harrison.ai launches Harrison.rad.1 radiology foundation model
- 2024-08Harrison.ai's hydrocephalus tool gets FDA Breakthrough Designation and Medicare NTAP code
Revision history
26 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Australian health tech startup Harrison.ai scores $112M Series C (2025-02-11)
- Harrison.ai - Headcount, Funding & Open Jobs (2026-07-16)
- Harrison.ai banks $179m in mammoth Series C (2025-02-11)
- Harrison.ai raises $112M as AI continues healthtech jolt
- Harrison.ai Stock Price, Funding, Valuation, Revenue & Financial Statements (2026-05-24)
- Harrison.ai unifies global brand to accelerate healthcare AI innovation (2025-10-07)
- Mass General Brigham collaboration
- Harrison.ai Teams
- annalise.ai Receives FDA Clearance and Breakthrough Device Designation
- Medicare New Technology Add-on Payment (NTAP) granted
- Pathology AI for Digital & Traditional Pathology
- Harrison.ai Radiology Foundation Model